CBIHOTCServices-Commercial Physical & Biological ResearchFiscal year ends May 31
Cannabis Bioscience International Holdings, Inc.
Financials through Q3 FY2026, quarter ended Feb 28, 2026Last filing: 10-Q on Apr 16, 2026
$0.00+0.00 (+33.33%)
Close on Oct 19, 2026
- Market cap
- $2.33M
- P/E (TTM)
- –
- Dividend yield
- –
Cannabis Bioscience International Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Clinical Trials [Member] | $301.73K | $213.87K | $267.22K | 99.6% | +41.1% |
| Merchandise [Member] | $1.29K | $4.41K | $22.30K | 0.4% | -70.7% |
| Seminar Fees [Member] | $0 | $1.93K | $16.43K | 0.0% | -100.0% |
| Consulting Fees [Member] | $0 | $28.64K | $8.33K | 0.0% | -100.0% |
| Royalty [Member] | – | $0 | $42 | – | – |
| Video Course [Member] | – | $0 | $2.50K | – | – |
By region
From the segment and revenue-disaggregation notes of Cannabis Bioscience International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.